Datum objave: 05.12.2022
Kategorija: Prosta delovna mesta
JAVNA OBJAVA PROSTEGA DELOVNEGA MESTA
Članica: FAKULTETA ZA FARMACIJO, Aškerčeva cesta 7, 1000 Ljubljana
Razpisano delovno mesto: RAZISKOVALEC – m/ž
- Šifra DM: H017004
- Tarifni razred: VII/2
- Število delovnih mest: 1
1. Pogoji za opravljanje dela
a) Zahtevana izobrazba: 7 raven izobrazbe/ visokošolska univ. izobrazba ali magistrska izobrazba (2. Bolonjska stopnja) naravoslovne smeri (farmacija, kemija)
b) Drugi pogoji za zasedbo delovnega mesta
Funkcionalna znanja in ostale zahteve: inovativnost, sposobnost za timsko delo, komunikativnost, aktivno znanje angleškega jezika. Zaželeno: izkušnje s področja organske sinteze, farmacevtske kemije ali vrednotenja novih spojin.
2. Kratek opis dela in nalog: Znanstveno-raziskovalno strokovno delo za izvedbo projekta: J7-4635 – MitoCan - Predklinični razvoj novih zaviralcev mitohondrijskih ionskih kanalov za zdravljenje raka ali projekta: J1-3030 - MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance; strokovno sodelovanje z naročnikom nalog in ostalimi raziskovalci, priprava pisnih poročil in elaboratov o raziskavah ter ekspertizah.
J1-3030 - MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance There is an urgent need for new therapies and new antibiotics to treat deadly infections caused by so-called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) which are often resistant to available antibiotics. Antimicrobial resistance (AMR) is becoming an increasingly urgent public health threat in both clinical and community settings. One promising strategy to address this rapid evolution of resistance is the design of antimicrobial compounds that equipotently inhibit two bacterial targets. The rationale for this approach is that the development of resistance to multitargeting antibiotics (MTA) would require the simultaneous occurrence of multiple specific mutations at both targets, which is extremely rare. In the MTAvsAMR (new MultiTargeting Antibiotics against AntiMicrobial Resistance) research project, we aim to develop a new structural class of MTA against two well-established molecular targets with innovative approaches to potent and safe multitargeting antibiotics with limited resistance. We will target the antibacterial activity of the new molecules against ESKAPE pathogens to address an unmet medical need, with a target product profile of methicillin-resistant (MRSA), vancomycin-intermediate (VISA) Staphylococcus aureus and Acinetobacter baumannii clinical isolates. To overcome the limitations of the current multitargeting antibiotics and to drive further development, we have established an interdisciplinary consortium to address fundamental questions related to the design of new antibacterial compounds with limited resistance, suitable PADMET properties, and lower susceptibility to efflux mechanisms.
Or
J7-4635 – MitoCan – Preclinical development of new mitochondrial Kv1.3 inhibitors for the treatment of cancer Ion channels are now considered unconventional, promising oncological targets, whose expression is often altered in cancer cells and which are emerging as critical players in tumorigenesis. The idea of targeting Kv1.3 ion channels directly in mitochondria, whose function critically depends on ion fluxes and which are crucial for both cell survival and apoptosis, could change the therapeutic field of cancer research. Resistance to apoptosis is one of the key hallmarks of cancer cells and often arises as a mechanism to escape drug-induced toxicity. Kv1.3 is also important for immune cells, which are a central component of the tumour microenvironment, both at the primary site and–more importantly for metastasis–at the distant location of the metastatic tumour. Therefore, it is reasonable to postulate that ion channel-based therapies may be beneficial in preventing and eradicating metastasis and may be useful in cells that are resistant to classical chemotherapy. MitoCan (Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy) is an innovative project aimed at targeting cancer by utilizing mitochondrial Kv1.3 ion channels with proof of principle in in vivo model of cancer. MitoCan is based on two new patent applications (HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS and MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS) and newly developed results, which indicate that MitoCan selective and potent mitochondrial Kv1.3 inhibitors have a great potential for lead optimization and preclinical development. Mitocan joins international partners that are the discoverers and undisputed leaders in research of cancer and ion channels in cancer together with the most important Slovenian research institutes to make a breakthrough in the potential of ion channels for the treatment of cancer.
3. Sklenitev delovnega razmerja je za določen od 1. 1. 2023 do 30. 9. 2024 (ali vsaj za eno leto), s polnim delovnim časom.
Poskusna doba: 3 mesece
4. Rok za prijavo: do 16. 12. 2022
Univerza v Ljubljani spodbuja enakost spolov pri zaposlovanju.
Kandidati posredujejo vlogo, CV, predstavitev dosedanjega dela in osebnih ciljev, dokazila o izobrazbi, izvolitvi v naziv, citiranosti, bibliografijo itd., na naslov Univerza v Ljubljani, Fakulteta za farmacijo, Aškerčeva c. 7, 1000 Ljubljani ali po elektronski pošti na ks@ffa.uni-lj.si.
Osebne podatke prijavljenega kandidata bo članica Univerze v Ljubljani – Fakulteta za farmacijo, Aškerčeva c. 7, Ljubljana, obdelovala za namen razpisa za prosto delovno mesto oz. za namen sklepanja pogodbe o zaposlitvi ter v okviru ZDR-1, ZJU in ZSPJS*. V primeru zaposlitve se bodo kandidatovi podatki hranili trajno, sicer pa (če za daljšo hrambo kandidat ne da svoje osebne privolitve) do izteka pritožbenih rokov (30 dni po izbiri kandidata). Če kandidat svojih osebnih podatkov ne želi posredovati, se njegova vloga ne more obravnavati.
Kandidat lahko od Fakultete za farmacijo Univerze v Ljubljani kadarkoli zahteva pravico dostopa in izbrisa (do sklenitve pogodbe o zaposlitvi) osebnih podatkov, popravek, omejitev obdelave ter pravico do prenosljivosti podatkov. Za pomoč pri uveljavljanju svojih pravic, se kandidat lahko obrne na pooblaščeno osebo za varstvo podatkov Univerze v Ljubljani (dpo@uni-lj.si). Če bo menil, da se njegovih pravic ne izvršuje ustrezno, se lahko pritoži informacijskemu pooblaščencu RS.
Fakulteta za farmacijo Univerze v Ljubljani si pridržuje pravico, da v skladu s pogodbeno svobodo po 24. členu ZDR-1, kandidata ne izbere, kljub temu, da izpolnjuje pogoje.
5. Kontaktna oseba na članici:
Marjetka Kirin
Telefonska številka: 4769-505
e-mail: marjetka.kirin@ffa.uni-lj.si